Top Story

FDA expands approval of Promacta

August 26, 2014

The FDA today expanded the improved indications for eltrombopag to include treatment of patients with severe aplastic anemia who demonstrated an insufficient response to immunosuppressive therapy, according to the agent’s manufacturer.

Eltrombopag (Promacta, GlaxoSmithKline), an oral thrombopoietin receptor agonist, already had been approved for treatment of thrombocytopenia in patients with chronic hepatitis C, as well as those with chronic immune thrombocytopenia who demonstrated insufficient response to immunoglobulins, corticosteroids or splenectomy.

In the Journals

Post-hospitalization intervention strategy yielded higher smoking cessation rates

August 26, 2014
Adult smokers recently released from the hospital achieved higher 6-month smoking cessation rates when they followed a post-discharge strategy compared with standard…

Novartis’ BioCamp addresses issues of aging with students

August 26, 2014
More than 60 university students from 25 countries are scheduled to attend Novartis’ 11th annual Biotechnology Leadership Camp this week in Basel, Switzerland. The…
FDA News

FDA grants orphan drug status to cannabidiol for glioblastoma multiforme

August 26, 2014
Insys Therapeutics recently announced that the FDA has granted orphan drug designation to a pharmaceutical cannabidiol for the treatment of glioblastoma…
More News Headlines »

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »